Navigation Links
Erythema in Medical Technology

Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium

... lesion count (papules and pustules), severity of erythema (redness) and telangiectasia (spider veins) and ... in 80% of subjects, including reduction of erythema and papules. The investigators saw ... a 90% improvement in lesions, 45% improvement in erythema and a 28% improvement in telangiectasia. The ...

Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study

... study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea - NAPA, Calif., May 4 ... improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... (1-2 mg/kg) for 1-2 weeks concomitantly with imatinib should be considered at the initiation of therapy. Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... reactions (more than 25%) in pediatric patients receiving PEGINTRON/REBETOL are pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema and vomiting. In a study with PEGINTRON/REBETOL (weight-based) combination therapy in adult patients, anemia with weight-based dosing was 29%; ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... during post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal). About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... during post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal). About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... reactions (more than 25%) in pediatric patients receiving PEGINTRON/REBETOL are pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema and vomiting. In a study with PEGINTRON/REBETOL (weight-based) combination therapy in adult patients, anemia with weight-based dosing was 29%; ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... reactions (more than 25%) in pediatric patients receiving PEGINTRON/REBETOL are pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema and vomiting. In a study with PEGINTRON/REBETOL (weight-based) combination therapy in adult patients, anemia with weight-based dosing was 29%; ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and GI perforation. Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several post marketing ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure and GI perforation. Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several post-marketing ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... (1-2 mg/kg) for 1-2 weeks concomitantly with Gleevec should be considered at the initiation of therapy. Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several postmarketing ...

Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing

... burn scar formation with the use of collagenase, an enzymatic debriding agent. Wound, 2005; 17[12]: 332-336. *Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after 1 year of ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... during post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal). About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the ...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

... were in excess of $200 million. Navelbine and its generic equivalents are often associated with injection site reactions, including phlebitis, erythema and pain at the site of injection. Studies have shown these reactions occur in approximately one-third of patients, with 5% of the reactions ...

Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea

... showed good tolerability and cosmetic acceptability. After 12 weeks there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. Transepidermal water loss measurements showed a 22% decrease in water loss, which supports an improvement in skin barrier function. In ...

Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections

... Patch continued to show a lack of dose limiting toxicities. Through multiple studies, the only side effect seen so far has been limited to transient erythema (redness of the skin). Julianna Lisziewicz, Ph.D., Co-Founder and CEO of Genetic Immunity, said, "The distinctive safety and immunogenicity data is ...

New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy

... HIV to others. -- Severe and potentially life-threatening skin reactions, including Stevens-Johnson Syndrome, hypersensitivity reaction, and erythema multiforme, have occurred ( Treatment with INTELENCE should be discontinued and appropriate therapy initiated if severe rash develops ...

Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

... anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), ...

Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

... anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), ...

Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer

... with stable disease for more than six months. To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema (hand-foot syndrome), Grade 3 AST elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg (intermittent ...

Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration

... effect. Please refer to ritonavir prescribing information for additional information on precautionary measures. Severe skin rash, including erythema multiforme and Stevens-Johnson Syndrome, has been reported in subjects receiving PREZISTA during the clinical development program. In some cases, ...

MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule

... anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), ...

Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting

... levels of ragweed allergic rhinitis and as a result, no meaningful clinical effect could be measured. Abstract #31 (ID 385836) entitled, "Wheal and erythema to ragweed extract are distinct predictors of symptom scores in ragweed allergic patients," was part of Concurrent Session "D" on Immunotherapy ...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

... 99 for the 13 week treatment cohort. There were no Serious Adverse Events in the study, and the most common Adverse Event was transient, painless erythema at the site of injection. There was no effect on liver synthetic function as indicated by changes in bilirubin and albumin levels and prothrombin ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... during trials. Skin and subcutaneous tissue: Very common: Rash/desquamation, alopecia. Common: Urticaria, allergic reaction/hypersensitivity, erythema multiforme, pruritus. Cardiovascular and cerebrovascular: Uncommon: Myocardial infarction, angina pectoris, cerebrovascular accident, arrhythmias, ...

New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy

... effect. Please refer to ritonavir prescribing information for additional information on precautionary measures. Severe skin rash, including erythema multiforme and Stevens-Johnson Syndrome, has been reported in subjects receiving PREZISTA during the clinical development program. In some cases, ...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

... anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), ...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

... (83.9 percent vs. 75.4 percent), swelling (25.4 percent vs. 15.8 percent), erythema (24.6 percent vs. 18.4 percent), fever (10.3 percent vs. 8.6 percent), ... Swelling 25.4 15.8 7.3 erythema 24.6 18.4 12.1 Pruritus ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

... (83.9 percent vs. 75.4 percent), swelling (25.4 percent vs. 15.8 percent), erythema (24.6 percent vs. 18.4 percent), fever (10.3 percent vs. 8.6 percent), ... Swelling 25.4 15.8 7.3 erythema 24.6 18.4 12.1 Pruritus ...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

... (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). ... leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). ...

Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study

... and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated Bullous dermatologic reactions (eg, erythema multiforme and Stevens- Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several ...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

... joint stiffness (1%), myalgia (1%), carpel tunnel syndrome (1%), loss of consciousness (1%), respiratory distress (1%), dermatitis exfoliative (1%), erythema (1%), and rash generalized (1%). The frequency of SAEs decreased after the first two cycles of treatment. The percentage of patients overall who ...

Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

... weeks 8 and 12 versus approximately 10% reduction for placebo. Statistically significant differences as compared to placebo were not achieved for the erythema or pruritus scores which were less severe at baseline. The drug was well-tolerated across both active treatment arms, and there were no reports of ...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

... effect. Please refer to ritonavir prescribing information for additional information on precautionary measures. Severe skin rash, including erythema multiforme and Stevens-Johnson Syndrome, has been reported in subjects receiving PREZISTA during the clinical development program. In some ...
Other Contents
(Date:9/30/2014)... and strawberries all have in common? Unlike most ... and are diploid, these organisms are all polyploid, meaning ... and salmon have 3 and 4 sets of chromosomes, ... seem surprising, in fact most plant species are polyploid. ... century ago, but only recently, with the development of ...
(Date:9/30/2014)... Salk professor and Howard Hughes Medical Institute investigator, ... named recipients in the 2014 round of grants ... the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... announced September 30, provides more than $3 million ... years. , The BRAIN Initiative, launched last year, ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Salk scientists receive $3 million for BRAIN Initiative grant 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
(Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... 2014 First Warning Systems, a pioneer ... changes throughout the body, announced the company is changing ... the company’s breadth of upcoming product releases. The initial ... technology. , “Our initial focus will be an ‘Internet ... abnormal circadian cellular changes over time,” said Rob Royea, ...
(Date:10/1/2014)... Join the more than 80 golfers who already ... ever charity golf tournament to benefit Project HEAL, a not-for-profit ... cannot afford treatment. The tournament will be held Monday, Oct. ... , The day-long event starts with 10:30 a.m. check-in and ... will begin at 5 p.m. and will include an auction ...
(Date:10/1/2014)... 01, 2014 Innovations announces the upcoming ... broadcast on Monday, October 20, 2014 at 7:30 a.m. ... will go behind the scenes to learn about Break ... will explore the practical help and information Break the ... the warning signs of abuse, how to navigate the ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
Other TagsOther Tags